Anika Therapeutics, Inc. (ANIK) vs Upstream Bio, Inc. (UPB)
A side-by-side comparison of Anika Therapeutics, Inc. and Upstream Bio, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ANIK
Anika Therapeutics, Inc.
$19.12HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
UPB
Upstream Bio, Inc.
$4.59HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — ANIK vs UPB
growth of $100 · dividends reinvested · last 2yANIK -22.7% (-12.1%/yr)UPB -78.0% (-53.0%/yr)ANIK compounded faster over this window
ANIK UPB
ANIK vs UPB: by the numbers
- •ANIK is the larger company ($256M vs $250M market cap).
- •Both run net losses; ANIK's is the smaller (-3.14% vs -4955.67% net margin).
Metrics side by side
Valuation
| Metric | ANIK | UPB |
|---|---|---|
| Forward P/E | 18.21 | N/A |
| P/S ratio | 2.12 | 79.10 |
| P/B ratio | 1.86 | 0.92 |
| EV / EBITDA | 473.06 | N/A |
| FCF yield | 0.22% | N/A |
Profitability
| Metric | ANIK | UPB |
|---|---|---|
| Gross margin | 62.16% | 98.45% |
| Operating margin | -4.24% | -5618.82% |
| Net margin | -3.14% | -4955.67% |
| ROE | -2.76% | -57.76% |
| ROIC | -3.17% | -62.51% |
Growth (annualized)
| Metric | ANIK | UPB |
|---|---|---|
| Revenue CAGR (5Y) | -2.48% | N/A |
| FCF CAGR (5Y) | -39.38% | N/A |
| Total return CAGR (5Y) | -13.40% | N/A |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.